Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $56.1 million.

  • 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) rose 1.03% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 1.03%. This contributed to the annual value of $53.9 million for FY2024, which is 37.86% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $56.1 million for Q3 2025, which was up 0.36% from $55.9 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $56.1 million during Q3 2025, with a 5-year trough of $26.7 million in Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $53.9 million (2024), whereas its average is $48.6 million.
  • Data for 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 50.57% (in 2024) over the last 5 years.
  • 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $27.7 million in 2021, then climbed by 16.66% to $32.4 million in 2022, then climbed by 20.95% to $39.1 million in 2023, then soared by 37.86% to $53.9 million in 2024, then grew by 1.03% to $56.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $56.1 million in Q3 2025, compared to $55.9 million in Q2 2025 and $55.7 million in Q1 2025.